Lumosa Therapeutics Co., Ltd.

Lumosa President     Chairman: Dr. Chang-Hai TsaiLumosa logo 01 
     Founded Date: 2000/11/13
     Tel: +886-2-26557918
     Address: 4th Floor, No. 3-2, Park Street, Nangang District, Taipei, 11503, Taiwan
     Website: http://www.lumosa.com.tw 


 

Company Profile:

Lumosa Therapeutics is dedicated to the development of innovative new drugs for the treatment of unmet medical needs in the fields of neurological and inflammatory diseases. Lumosa Therapeutics is actively engaged in scientific licensing and new drugs development under a “reSEARCH and DEVELOPMENT” model. Through our expertise in translational research, project management, patent management and licensing strategy, we plan for product lifecycle management at the inception of the projects, optimize the development process and maximize the value of our products for out-licensing. Our very capable multi-functional team who are experienced in in vitro & in vivo pharmacology, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development. Our project managers and subject matter experts work seamlessly to efficiently identify, select and develop novel drug products with global market potential, and collaborate with our international partners in clinical trials, and product development.

Pipeline:

New Drug Indications Core Strength Current Phase

1.LT1001

Long-acting Analgesic for Moderate to Severe pain 

long‐acting analgesic effect, high safety profile, great pharmaco‐economic value

Gained TFDA Marketing Approval

2. LT3001

Acute Ischemic Stroke 

Dissolves blood clot, and reduces the volume of the embolism without altering coagulation time.

Scheduled to  file US FDA IND in 2H 2017

3. CS010

Itch

 (Nonpublic Information)  Research

4.CS011

Animal Pain Management

 (Nonpublic Information)  Research